Skip to Main Content

Paper Details

Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma.
J Clin Oncol
72
2023
Advanced Melanoma, Patients, Pembrolizumab, T, T-VEC, VEC, advanced melanoma, antiprogrammed cell death protein-1, patients, pembrolizumab, stage IIIB-IVM1c unresectable melanoma
Author NameAffiliation
Antoni RibasJonsson Comprehensive Cancer Center at the University of California Los Angeles
Antoni RibasJonsson Comprehensive Cancer Center at the University of California Los Angeles
Georgina V LongMelanoma Institute Australia, The University of Sydney
Georgina V LongRoyal North Shore and Mater Hospitals
John M KirkwoodUPMC Hillman Cancer Center
Reinhard DummerUniversity Hospital of Zurich
Reinhard DummerUniversity Hospital of Zurich
  • 1 - 7

Datasets

Release 1.2